Cardinal Health (CAH)
(Delayed Data from NYSE)
$111.93 USD
-0.62 (-0.55%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $111.94 +0.01 (0.01%) 7:36 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$111.93 USD
-0.62 (-0.55%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $111.94 +0.01 (0.01%) 7:36 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
Zacks News
Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Cardinal Health (CAH) and Asensus Surgical (ASXC) have performed compared to their sector so far this year.
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
3 Top-Ranked Large-Caps to Buy for Growth
by Derek Lewis
Large-caps provide many meaningful advantages, including a less volatile approach, dividend payouts, and greater analyst coverage.
Masimo (MASI) Posts Preliminary Q4 Results, Issues FY24 View
by Zacks Equity Research
Masimo's (MASI) fourth-quarter 2023 results are likely to reflect the impacts of the robust adoption of hearable products.
Should JPMorgan Diversified Return U.S. Mid Cap Equity ETF (JPME) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JPME
Integer Holdings (ITGR) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
Integer Holdings' (ITGR) revenue growth in the fourth quarter is likely to have been boosted by continued strong customer demand for its products.
Cardinal Health (CAH) Streamlines Operation With New Structure
by Zacks Equity Research
Cardinal Health's (CAH) new reporting structure is likely to streamline operations, providing better visibility of growth areas. At-home solutions and OptiFreight Logistics are possibly the key value creators.
Zacks.com featured highlights include Live Oak Bancshares, Marriott International, Cardinal Health, Fabrinet and Wingstop
by Zacks Equity Research
Live Oak Bancshares, Marriott International, Cardinal Health, Fabrinet and Wingstop are part of the Zacks Screen of the Week article.
5 Stocks in S&P 500 ETF That Braved the Worst Start Since 2016
by Sweta Killa
The S&P 500 had the worst start to a year since 2016, reflecting a sharp reversal of the roaring rally in the final two months of 2023. Despite the losses, some stocks in the ETF stood tall.
AngioDynamics (ANGO) Q2 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in second-quarter fiscal 2024.
5 Low-Leverage Stocks to Buy Amid Mixed Investor Sentiments
by Aparajita Dutta
The crux of safe investment lies in choosing a company that is not burdened with debt, as a debt-free stock is almost impossible to find. You may buy LOB, MAR, CAH, FN and WING.
5 Impressive MedTech Industry Growth Stocks to Buy for 2024
by Moumi Mondal
Stocks such as HAE, PEN, EXAS, PODD and CAH are set to garner remarkable growth for investors.
Wingstop and Marriott Vacations Worldwide have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Wingstop and Marriott Vacations Worldwide are part of the Zacks Bull and Bear of the Day article.
Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?
by Zacks Equity Research
Here is how Aurinia Pharmaceuticals (AUPH) and Cardinal Health (CAH) have performed compared to their sector so far this year.
3 Top Dividend Aristocrats to Buy Ahead of 2024
by Tirthankar Chakraborty
Some of the dividend aristocrats, such as Cardinal Health (CAH), Atmos Energy (ATO) and NextEra Energy (NEE), have a better-quality business and strong underlying fundamentals.
Should Invesco Russell 1000 Dynamic Multifactor ETF (OMFL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for OMFL
5 Broker-Favorite Stocks to Keep an Eye on as 2024 Approaches
by Maharathi Basu
We believe that stocks like American Airlines (AAL), ABM Industries (ABM), Cardinal Health (CAH), Cleveland-Cliffs (CLF) and Cencora (COR) should be on an investor's watchlist.
Cardinal Health, Inc. (CAH) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Cardinal Health (CAH) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Medical Stocks Lagging Cardinal Health (CAH) This Year?
by Zacks Equity Research
Here is how Cardinal Health (CAH) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
Reasons to Add Cardinal Health (CAH) to Your Portfolio Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from a solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cardinal (CAH) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Cardinal (CAH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What's in Store for Cooper Companies (COO) in Q4 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) fiscal fourth-quarter results are likely to reflect segmental strength.
McKesson (MCK) Announces Availability of FDA-Cleared Drug
by Zacks Equity Research
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for breast cancer.